+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Premature Ejaculation Treatment Market by Treatment Type, End User, Dosage Form - Global Forecast to 2030- Product Image
Premature Ejaculation Treatment Market by Treatment Type, End User, Dosage Form - Global Forecast to 2030- Product Image
Sale

Premature Ejaculation Treatment Market by Treatment Type, End User, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968711
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Premature Ejaculation Treatment Market grew from USD 3.86 billion in 2024 to USD 4.24 billion in 2025. It is expected to continue growing at a CAGR of 9.84%, reaching USD 6.78 billion by 2030.

Setting the Stage for Evolving Premature Ejaculation Treatment

Premature ejaculation remains one of the most prevalent sexual health concerns affecting men worldwide, yet it continues to pose complex challenges for clinicians, researchers, and industry stakeholders. This section introduces the critical importance of understanding the evolving treatment landscape, exploring both established therapies and emerging innovations that aim to improve patient outcomes. By framing the market within a broader healthcare context, we establish a foundation for deeper analysis of transformative shifts and strategic imperatives.

Emerging Dynamics Shaping the Treatment Ecosystem

Recent years have witnessed a paradigm shift in the way premature ejaculation is diagnosed, managed, and perceived within medical communities. Advances in digital health have enabled remote monitoring of treatment adherence and efficacy, while telemedicine platforms are breaking down barriers to specialist consultations. Concurrently, there has been a notable surge in device-based interventions, with constrictive rings and vibratory stimulation tools gaining traction as alternatives or adjuncts to traditional pharmacotherapy. Regulatory bodies have responded by streamlining approval processes for low-risk digital and device solutions, accelerating time to market. In parallel, pharmaceutical innovators are exploring novel combinations of topical anesthetics with systemic agents to address both the physiological and psychological dimensions of the condition. These interconnected developments underscore a dynamic ecosystem where multidisciplinary collaboration and patient-centric approaches are redefining standards of care.

Navigating the Ripple Effects of US Tariff Adjustments

In 2025, newly imposed tariff measures in the United States have introduced additional complexity for stakeholders in premature ejaculation treatment. Import duties on specialized medical devices, including vibratory stimulators and constrictive rings, have risen, exerting upward pressure on manufacturing and distribution costs. Pharmaceutical supply chains have also been disrupted by levies on active pharmaceutical ingredients imported from key international markets. In response, manufacturers are reevaluating sourcing strategies, seeking to localize production and mitigate risk exposure. This reconfiguration has prompted some organizations to invest in domestic contract manufacturing, while others are renegotiating supplier agreements to safeguard profit margins. Despite these headwinds, many companies are leveraging economies of scale and optimizing logistics to buffer end users from sudden price increases. As a result, market participants are demonstrating resilience through adaptive supply chain frameworks and dynamic pricing models.

Dissecting Treatment Modalities and Care Settings to Inform Strategy

A nuanced understanding of patient needs and care settings is critical for segmentation strategy. Based on treatment type, non-pharmacological approaches encompass behavioral therapy methodologies such as sensate focus and start-stop technique, alongside device interventions that include constrictive rings and vibratory stimulation tools. Within pharmacological systemic therapies, phosphodiesterase inhibitors are represented by sildenafil and tadalafil, while selective serotonin reuptake inhibitors feature both dapoxetine and off-label options like fluoxetine, paroxetine, and sertraline. Topical formulations rely on local anesthetics delivered via lidocaine cream, lidocaine-prilocaine spray, and prilocaine cream. Examining settings of care, clinics remain pivotal for supervised intervention protocols, whereas home care environments facilitate discreet self-management supported by digital adherence tools, and hospitals provide integrated treatment pathways for complex cases. Finally, dosage form considerations reveal preferences across creams, sprays, and tablets, each offering distinct advantages in ease of administration, onset of action, and patient acceptance. These intersecting frameworks underscore the need for tailored strategies that address treatment modality, end-user environment, and formulation preferences simultaneously.

Capitalizing on Diverse Regional Market Drivers

Regional dynamics shape both demand and regulatory landscapes in profound ways. In the Americas, strong healthcare infrastructure and a growing emphasis on male sexual health have driven adoption of both established pharmacotherapies and emerging device-based solutions. Market access strategies often focus on reimbursement pathways and physician education programs to expand reach. In Europe, Middle East & Africa, diverse regulatory environments and socio-cultural attitudes necessitate adaptive commercialization frameworks; localized trials and targeted advocacy are crucial for market entry. The Asia-Pacific region presents a tapestry of maturity levels, where advanced economies accelerate digital health integration while emerging markets emphasize affordable generics and over-the-counter topical treatments. Regulatory harmonization efforts in ASEAN and regional trade collaborations are creating new avenues for cross-border distribution. By aligning product development and go-to-market tactics with these nuanced regional drivers, organizations can optimize penetration and drive sustainable growth across global territories.

Unveiling Competitive Strategies Among Industry Leaders

Leading players across the premature ejaculation treatment landscape are forging distinct competitive advantages. Pharmaceutical giants are enhancing their systemic portfolios through strategic partnerships and pipeline expansions that blend established phosphodiesterase inhibitors with next-generation serotonergic agents. Generic manufacturers are leveraging robust manufacturing capabilities to supply high-quality off-patent SSRIs and topical anesthetics at competitive price points. Device innovators are harnessing biomedical engineering breakthroughs to deliver wearable stimulatory solutions that integrate seamlessly with telehealth platforms, thereby strengthening patient engagement. Collaborations between device and pharmaceutical entities are also on the rise, resulting in combination therapies that address both neurological pathways and peripheral sensitivity. Additionally, contract research organizations are facilitating rapid clinical validation for new interventions, accelerating regulatory submissions and market entry. Collectively, these company-level maneuvers highlight an industry characterized by convergence, agility, and an unwavering focus on improving clinical outcomes.

Strategic Imperatives to Drive Sustainable Market Leadership

To maintain a competitive edge, industry leaders must adopt a multi-pronged approach. First, investment in integrated digital platforms will support remote monitoring, personalize treatment pathways, and enhance adherence. Second, diversifying supply chains by establishing regional manufacturing hubs and alternative sourcing agreements will mitigate tariff-driven cost pressures and ensure consistent product availability. Third, fostering cross-disciplinary collaborations between behavioral health specialists, urologists, and biomedical engineers can catalyze the development of hybrid solutions that combine pharmacological and device modalities. Fourth, engaging proactively with regulatory agencies to shape policy and expedite approvals will accelerate time to market. Finally, comprehensive educational initiatives targeting healthcare providers and patients will be instrumental in destigmatizing treatment, improving uptake, and driving long-term retention. By implementing these strategic imperatives, organizations can navigate complexity and position themselves as thought leaders in a rapidly evolving arena.

Evidence-Based Methodology Underpinning Analytical Rigor

This analysis employs a rigorous mixed-methodology framework to ensure validity and reliability. Secondary research included systematic review of peer-reviewed journals, regulatory filings, and patent databases to map technological advancements and therapy approvals. Primary insights were collected through in-depth interviews with key opinion leaders, including urologists, sexual health therapists, and medical device engineers, to capture frontline perspectives on treatment efficacy and patient adherence. Data triangulation techniques were applied to reconcile disparities between qualitative inputs and quantitative metrics, while validation panels comprising industry experts vetted preliminary findings to enhance accuracy. Competitive benchmarking was conducted through detailed profiling of leading companies, examining R&D pipelines, partnership models, and market access strategies. This structured approach ensures that conclusions and recommendations are grounded in comprehensive evidence, providing stakeholders with actionable intelligence to support informed decision-making.

Synthesis of Insights for Future-Ready Treatment Strategies

The journey through market dynamics, regulatory shifts, segmentation complexities, and competitive maneuvers underscores the multifaceted nature of premature ejaculation treatment. A confluence of digital health innovation, novel combination therapies, and strategic supply chain realignments is reshaping how care is delivered and commercialized. Regional variations demand bespoke approaches, while tariff considerations call for resilient operational frameworks. As companies continue to invest in research, collaboration, and patient education, the industry stands poised to deliver more personalized, effective, and accessible solutions. The insights presented here provide a comprehensive lens for stakeholders to refine strategies, anticipate challenges, and harness opportunities in this critical area of men's health.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Non Pharmacological
      • Behavioral Therapy
        • Sensate Focus
        • Start Stop Technique
      • Devices
        • Constrictive Ring
        • Vibratory Stimulation
    • Pharmacological Systemic
      • Phosphodiesterase Inhibitors
        • Sildenafil
        • Tadalafil
      • Selective Serotonin Reuptake Inhibitors
        • Dapoxetine
        • Off Label Ssris
          • Fluoxetine
          • Paroxetine
          • Sertraline
    • Topical
      • Local Anesthetics
        • Lidocaine Cream
        • Lidocaine Prilocaine Spray
        • Prilocaine Cream
  • End User
    • Clinics
    • Home Care
    • Hospitals
  • Dosage Form
    • Creams
    • Sprays
    • Tablets
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Menarini Group
  • Teva Pharmaceuticals Industries Ltd.
  • Cipla Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Panacea Biotec Ltd.
  • IBSA Institut Biochimique SA
  • Endo International plc
  • Reckitt Benckiser Group plc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Premature Ejaculation Treatment Market, by Treatment Type
8.1. Introduction
8.2. Non Pharmacological
8.2.1. Behavioral Therapy
8.2.1.1. Sensate Focus
8.2.1.2. Start Stop Technique
8.2.2. Devices
8.2.2.1. Constrictive Ring
8.2.2.2. Vibratory Stimulation
8.3. Pharmacological Systemic
8.3.1. Phosphodiesterase Inhibitors
8.3.1.1. Sildenafil
8.3.1.2. Tadalafil
8.3.2. Selective Serotonin Reuptake Inhibitors
8.3.2.1. Dapoxetine
8.3.2.2. Off Label Ssris
8.3.2.2.1. Fluoxetine
8.3.2.2.2. Paroxetine
8.3.2.2.3. Sertraline
8.4. Topical
8.4.1. Local Anesthetics
8.4.1.1. Lidocaine Cream
8.4.1.2. Lidocaine Prilocaine Spray
8.4.1.3. Prilocaine Cream
9. Premature Ejaculation Treatment Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Home Care
9.4. Hospitals
10. Premature Ejaculation Treatment Market, by Dosage Form
10.1. Introduction
10.2. Creams
10.3. Sprays
10.4. Tablets
11. Americas Premature Ejaculation Treatment Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Premature Ejaculation Treatment Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Premature Ejaculation Treatment Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Menarini Group
14.3.2. Teva Pharmaceuticals Industries Ltd.
14.3.3. Cipla Limited
14.3.4. Lupin Limited
14.3.5. Sun Pharmaceutical Industries Ltd.
14.3.6. Sandoz International GmbH
14.3.7. Panacea Biotec Ltd.
14.3.8. IBSA Institut Biochimique SA
14.3.9. Endo International plc
14.3.10. Reckitt Benckiser Group plc
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. PREMATURE EJACULATION TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. PREMATURE EJACULATION TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. PREMATURE EJACULATION TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PREMATURE EJACULATION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PREMATURE EJACULATION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PREMATURE EJACULATION TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE PRILOCAINE SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRILOCAINE CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 74. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 75. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 76. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 77. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 80. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 81. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 82. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. CANADA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 84. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 88. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 89. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 93. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 145. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 147. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 148. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 149. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 150. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 154. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 157. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 159. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 160. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 161. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 162. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 166. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 167. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FRANCE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 181. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 183. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 184. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 185. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 186. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 189. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 190. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 191. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. ITALY PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 195. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 196. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 197. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 198. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 201. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 202. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SPAIN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 243. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 244. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 245. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 246. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 250. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. DENMARK PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 265. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 267. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 268. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 269. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 270. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 273. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 274. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 275. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. QATAR PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 279. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 280. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 281. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 282. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 283. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2030 (USD MILLION)
TABLE 285. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 286. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2030 (USD MILLION)
TABLE 287. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. FINLAND PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 293.

Companies Mentioned

The companies profiled in this Premature Ejaculation Treatment market report include:
  • Menarini Group
  • Teva Pharmaceuticals Industries Ltd.
  • Cipla Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Panacea Biotec Ltd.
  • IBSA Institut Biochimique SA
  • Endo International plc
  • Reckitt Benckiser Group plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.78 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Premature Ejaculation Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Premature Ejaculation Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Premature Ejaculation Treatment - Global Strategic Business Report - Product Image

Premature Ejaculation Treatment - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Premature Ejaculation Treatment Market Report 2025 - Product Image

Premature Ejaculation Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Premature Ejaculation - Pipeline Insight, 2025 - Product Image

Premature Ejaculation - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Premature Ejaculation Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Premature Ejaculation Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 90 Pages
  • Global
From

About the Premature Ejaculation Drug Market

The Premature Ejaculation Drug market is a subset of the Sexual and Reproductive Health Drugs market. It is composed of drugs used to treat premature ejaculation, a condition in which a man ejaculates too quickly during sexual intercourse. These drugs are typically taken orally and work by increasing the time it takes for a man to ejaculate. Common side effects of these drugs include dizziness, headache, and nausea. The Premature Ejaculation Drug market is growing due to increased awareness of the condition and the availability of treatments. This has led to an increase in demand for these drugs, as well as an increase in research and development of new drugs. Some companies in the Premature Ejaculation Drug market include Pfizer, Eli Lilly, and Johnson & Johnson. These companies are involved in the research, development, and marketing of drugs to treat premature ejaculation. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.